MERCK KGAA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 151.8 EUR | +1.10% |
|
+3.94% | +5.31% |
| 04-26 | Former SAP Executive Board member Kleinemeier to permanently head Merck's Supervisory Board | DP |
| 04-25 | Scholz pledges further support for the pharmaceutical industry | DP |
| Sales 2024 * | 21.25B 22.72B 1,819B | Sales 2025 * | 22.5B 24.06B 1,927B | Capitalization | 65.98B 70.54B 5,649B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.97B 3.18B 254B | Net income 2025 * | 3.48B 3.72B 298B | EV / Sales 2024 * | 3.42 x |
| Net Debt 2024 * | 6.79B 7.26B 581B | Net Debt 2025 * | 4.83B 5.17B 414B | EV / Sales 2025 * | 3.15 x |
| P/E ratio 2024 * |
22.2
x | P/E ratio 2025 * |
18.9
x | Employees | 62,908 |
| Yield 2024 * |
1.52% | Yield 2025 * |
1.59% | Free-Float | 29.71% |
More Fundamentals
* Assessed data
More news
Latest transcript on Merck KGaA
More press releases
| 1 day | +1.10% | ||
| 1 week | +3.94% | ||
| Current month | -7.24% | ||
| 1 month | -4.62% | ||
| 3 months | -2.66% | ||
| 6 months | +5.05% | ||
| Current year | +5.31% |
1 week
146.10
155.60
1 month
142.70164.85
Current year
140.50164.85
1 year
134.30172.40
3 years
134.30231.50
5 years
76.22231.50
10 years
59.38231.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 12/07/20 | |
Marcus Kuhnert
DFI | Director of Finance/CFO | 56 | 31/07/14 |
| Director of Finance/CFO | 53 | 25/04/19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Christian Raabe
BRD | Director/Board Member | - | - |
Jürgen Glaser
BRD | Director/Board Member | 61 | 30/04/12 |
Gabriele Eismann
BRD | Director/Board Member | 62 | 31/12/90 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.34% | 2 M€ | +13.56% | - | |
| 2.01% | 0 M€ | 0.00% | - | |
| 1.80% | 962 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 151.8 | +1.10% | 282,863 |
| 25/04/24 | 150.1 | -1.48% | 259,860 |
| 24/04/24 | 152.4 | -0.85% | 339,364 |
| 23/04/24 | 153.6 | +4.03% | 503,255 |
| 22/04/24 | 147.7 | +1.16% | 214,993 |
Delayed Quote Xetra, April 26, 2024 at 04:35 pm
More quotes
Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows:
- solutions and products for scientific and biotechnological research (44.2%);
- pharmaceutical products (38.4%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders, etc.;
- performance materials for the electronics industry (17.4%): semiconductor materials, liquid crystals, pigments and additives, carbon-based organic materials, etc.
Net sales are distributed geographically as follows: Germany (4.8%), Europe (24%), China (12.9%), Asia/Pacific (20.1%), the United States (26.8%), North America (1.6%), Latin America (6.3%), Middle East and Africa (3.5%).
Sector
Pharmaceuticals
Calendar
28/04/2024
- Ex-dividend day for final dividend
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
151.8
EUR
Average target price
182
EUR
Spread / Average Target
+19.93%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- MRK Stock
